That ought to follow in coming weeks.
There is currently no accepted treatment for Stargardt’s disease, and we will work diligently to go this European trial forward as fast as possible. .. ACT’s hESC-derived RPE cells receive EMA positive opinion for Orphan Medication Designation for Stargardt’s disease Advanced Cellular Technology, Inc. This opinion will now become forwarded by the EMA to the European Commission because of their adoption, that ought to follow in coming weeks. We are extremely very happy to receive this positive opinion for Orphan Drug Designation from the EMA for our hESC-derived RPE cells for the treatment of Stargardt’s disease, stated Gary Rabin, ACT’s interim chairman and CEO. (more…)